In this issue

Issue 105 • April 2021

“Two households, both alike in dignity.” Although Shakespeare wrote these words to describe two warring families in fair Verona, they could easily be applied to the meeting of two powerhouse industries in the healthcare space: Big Pharma and Big Tech.

As Big Tech’s interest in pharma grew, it seemed like the two industries were on route to collision. But what happens when Big Pharma and Big Tech join forces to drive innovation in healthcare? We find out.

Sticking with technology, we learn how the pharma industry is getting to grips with social media as traditional broadcast and print marketing falls out of favour with patients.

Elsewhere in this issue, we round up four key ways that the pharma industry can prepare for the next health pandemic, ask if Long Covid symptoms could help patients dealing with chronic fatigue symptoms, and examine a regulatory framework for the production, distribution and export of medical cannabis in the Isle of Man

Plus, we dive into the complex world of mRNA vaccines to find out if the treatment option has potential outside of infectious diseases, speak to the minds behind the Ineos Oxford Institute for AMR Research to find out what can be done to avoid AMR disaster, and take a look at the business and public benefits of embracing the public benefit corporation model.

All this and more in this latest issue of Pharma Technology Magazine.

Eloise Mclennan, editor

Go to article: Home | Big Tech meets Big PharmaGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: ProceedixGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: SanofiGo to article: ILC Dover Go to article: NiproGo to article: ACG WorldwideGo to article: CommentGo to article: Covid-19 vaccine effectiveness affected by variantsGo to article: Immuno-oncology high prescriber survey reveals top R&D strategiesGo to article: Using methotrexate may reduce the negative impact of high treatment-related costGo to article: Protecting against fake Covid-19 vaccinesGo to article: Cytiva Company Insight Go to article: CytivaGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: In DepthGo to article: Is big pharma and big tech working together a recipe for success?Go to article: Logging in: how the pharma industry is getting to grips with social media Go to article: Medical cannabis: regulating a new export market on the Isle of ManGo to article: Long Covid: could chronic fatigue syndrome be taken seriously at last?Go to article: Life after Covid-19: four ways to prepare for the next pandemicGo to article: mRNA vaccines: the post-pandemic outlook after a breakthrough yearGo to article: Staving off AMR disaster with Ineos and the University of OxfordGo to article: Public benefit: could the PBC model help pharma balance profits and patients?Go to article: The Solubility Company Insight Go to article: The Solubility companyGo to article: ButterworthGo to article: MicronovaGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue